eganelisib eganelisib eganelisib (usan), codenamed ipi-549, is an experimental drug being investigated as a possible treatment for cancer. it is a highly selective phosphoinositide 3-kinase inhibitor, and thus works by inhibiting the enzyme pik3cg, disrupting the pi3k/akt/mtor signaling pathway which plays important roles in the development of cancer. eganelisib clinical dataroutes ofadministrationoralatc codenoneidentifiers iupac name 2-amino-n--1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolopyrimidine-3-carboxamide cas number1693758-51-8pubchem cid91933883chemspider60600433uniifof5155fmzkeggd11896chemblchembl3984425pdb ligandv7y (pdbe, rcsb pdb)chemical and physical dataformulac30h24n8o2molar mass528.576 g·mol−13d model (jsmol)interactive image smiles cn1cc(cn1)c#cc6cccc2c6c(=o)n(c(=c2)c(c)nc(=o)c4c3ncccn3nc4n)c5ccccc5 inchi inchi=1s/c30h24n8o2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19h,1-2h3,(h2,31,35)(h,34,39)/t19-/m0/s1key:xumalordvcfwkv-ibgzpjmesa-n eganelisib is being developed by infinity pharmaceuticals. early clinical trial results were published in september 2016. on september 29, 2020, it was granted fast track designation by the united states food and drug administration (fda) as a treatment for inoperable, locally advanced, or metastatic triple-negative breast cancer, combined with a checkpoint inhibitor and chemotherapy. as of october 2020, five phase i/ii clinical trials were ongoing in the united states, and one in europe.